Modification of the activity of mitochondrial monoamine oxidases in vitro and in vivo
- PMID: 7340462
- DOI: 10.1007/BF01978790
Modification of the activity of mitochondrial monoamine oxidases in vitro and in vivo
Abstract
Treatment of bovine brain mitochondrial membranes with iproniazid (Ip) (1 mM, 15 min) inhibited monoamine oxidase (MAO) activity (substrates: 5-hydroxytryptamine, tyramine, dopamine) and significantly (about 7-fold) increased histamine deaminating activity (HDA). A selective inhibitor of MAO-A clorgyline (contrary to deprenyl) prevented the increase in HDA. Ip (200 mg/kg; within 10-16 h after parenteral administration) markedly (about 6-fold) increased the level of the HDA) in brain mitochondria of mice and guinea pigs. At the same time, a decrease in content of histamine (Hi) and increase in content of 5-hydroxytryptamine was noted in the brains of mice. In anesthetized and non-anesthetized guinea pigs Ip decreased (or prevented) the bronchoconstriction and toxic effects caused by Hi. The antihistamine effects of Ip are apparently due to its being able to induce reversible qualitative alteration (transformation) of the catalytic activity of the membrane-bound MAO of type A, which acquires as a result of this transformation potent HDA.
Similar articles
-
[Hydrazine derivative modification of the activity of brain mitochondrial monoamine oxidases].Vopr Med Khim. 1981 Nov-Dec;27(6):773-9. Vopr Med Khim. 1981. PMID: 7336653 Russian.
-
[Changes in substrate specificity of brain mitochondrial monoamine oxidase].Vopr Med Khim. 1977 May-Jun;(3):352-8. Vopr Med Khim. 1977. PMID: 888399 Russian.
-
Characteristics of mitochondrial and synaptosomal monoamine oxidase in monkey brain.Jpn J Pharmacol. 1984 Feb;34(2):211-9. doi: 10.1254/jjp.34.211. Jpn J Pharmacol. 1984. PMID: 6431160
-
Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs.Life Sci. 1974 Jun 1;14(11):2061-74. doi: 10.1016/0024-3205(74)90089-7. Life Sci. 1974. PMID: 4603266 Review. No abstract available.
-
Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.Neurotoxicology. 2004 Jan;25(1-2):243-50. doi: 10.1016/S0161-813X(03)00103-7. Neurotoxicology. 2004. PMID: 14697899 Review.
Cited by
-
The vagal ganglia transcriptome identifies candidate therapeutics for airway hyperreactivity.Am J Physiol Lung Cell Mol Physiol. 2018 Aug 1;315(2):L133-L148. doi: 10.1152/ajplung.00557.2017. Epub 2018 Apr 5. Am J Physiol Lung Cell Mol Physiol. 2018. PMID: 29631359 Free PMC article.